Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

793 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Single nucleotide polymorphisms in an intergenic chromosome 2q region associated with tissue factor pathway inhibitor plasma levels and venous thromboembolism.
Dennis J, Truong V, Aïssi D, Medina-Rivera A, Blankenberg S, Germain M, Lemire M, Antounians L, Civelek M, Schnabel R, Wells P, Wilson MD, Morange PE, Trégouët DA, Gagnon F. Dennis J, et al. Among authors: blankenberg s. J Thromb Haemost. 2016 Oct;14(10):1960-1970. doi: 10.1111/jth.13431. Epub 2016 Sep 17. J Thromb Haemost. 2016. PMID: 27490645 Free PMC article.
Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study.
Morange PE, Bickel C, Nicaud V, Schnabel R, Rupprecht HJ, Peetz D, Lackner KJ, Cambien F, Blankenberg S, Tiret L; AtheroGene Investigators. Morange PE, et al. Among authors: blankenberg s. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2793-9. doi: 10.1161/01.ATV.0000249406.92992.0d. Epub 2006 Oct 5. Arterioscler Thromb Vasc Biol. 2006. PMID: 17023678
Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study.
Morange PE, Blankenberg S, Alessi MC, Bickel C, Rupprecht HJ, Schnabel R, Lubos E, Münzel T, Peetz D, Nicaud V, Juhan-Vague I, Tiret L; Atherogene Investigators. Morange PE, et al. Among authors: blankenberg s. J Thromb Haemost. 2007 Mar;5(3):475-82. doi: 10.1111/j.1538-7836.2007.02372.x. Epub 2007 Jan 4. J Thromb Haemost. 2007. PMID: 17204132 Free article.
Polymorphisms of the tumor necrosis factor-alpha (TNF) and the TNF-alpha converting enzyme (TACE/ADAM17) genes in relation to cardiovascular mortality: the AtheroGene study.
Morange PE, Tregouet DA, Godefroy T, Saut N, Bickel C, Rupprecht HJ, Lackner K, Barbaux S, Poirier O, Peiretti F, Nalbone G, Juhan-Vague I, Blankenberg S, Tiret L. Morange PE, et al. Among authors: blankenberg s. J Mol Med (Berl). 2008 Oct;86(10):1153-61. doi: 10.1007/s00109-008-0375-6. Epub 2008 Jul 4. J Mol Med (Berl). 2008. PMID: 18600307
Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study.
Tregouet DA, Schnabel R, Alessi MC, Godefroy T, Declerck PJ, Nicaud V, Munzel T, Bickel C, Rupprecht HJ, Lubos E, Zeller T, Juhan-Vague I, Blankenberg S, Tiret L, Morange PE; AtheroGene Investigators. Tregouet DA, et al. Among authors: blankenberg s. J Thromb Haemost. 2009 Jan;7(1):49-57. doi: 10.1111/j.1538-7836.2008.03221.x. J Thromb Haemost. 2009. PMID: 19017260 Free article.
C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with unknown protein S-independent mechanism: results from genome-wide association and gene expression analyses followed by case-control studies.
Buil A, Trégouët DA, Souto JC, Saut N, Germain M, Rotival M, Tiret L, Cambien F, Lathrop M, Zeller T, Alessi MC, Rodriguez de Cordoba S, Münzel T, Wild P, Fontcuberta J, Gagnon F, Emmerich J, Almasy L, Blankenberg S, Soria JM, Morange PE. Buil A, et al. Among authors: blankenberg s. Blood. 2010 Jun 10;115(23):4644-50. doi: 10.1182/blood-2010-01-263038. Epub 2010 Mar 8. Blood. 2010. PMID: 20212171 Free PMC article.
793 results